ROSCUETherapeutics Secures $500,000 in Pre-Seed Funding for Mallia Therapeutics' Hair Loss Treatment Development

Mallia Therapeutics, a pioneering biopharmaceutical company at the forefront of innovative hair loss treatments, is thrilled to announce the successful completion of a $500,000 funding round. This substantial investment will accelerate the development of its flagship product, soluble CD83 (sCD83), which has shown promising results in preclinical trials for addressing hair loss effectively. Hair loss affects millions worldwide, often leading to emotional distress and impacting quality of life; thus, Mallia Therapeutics is committed to creating safe, efficacious solutions that empower individuals to regain their confidence. The funding will not only support the continuation of critical research and development but also facilitate further clinical trials, aiming to bring this game-changing treatment to market. Led by a team of experienced researchers and industry veterans, Mallia Therapeutics is dedicated to transforming the landscape of hair restoration through cutting-edge science. With this new capital in hand, the company is poised to make significant strides, and the team is eager to leverage this momentum to drive sCD83 towards its ultimate goal of providing a viable, non-invasive hair loss therapy. We look forward to sharing our journey with our investors, partners, and the community as we move closer to unveiling our groundbreaking therapy and improving the lives of those affected by hair loss. Stay tuned for more updates from Mallia Therapeutics, where innovation meets compassion in the quest for effective hair restoration treatments.